Back
ESC Premium Access

Eligible patients for the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk

Session: Poster Session 1 - Treatment of the chronic heart failure
Topic: Epidemiology, Prognosis, Outcome
Speaker: Doctor X. Chen (Gothenburg, SE)
Event: ESC Congress 2019

Congress Presentation

0

About the speaker

Doctor Xiaojing Chen

Sahlgrenska Academy, Gothenburg (Sweden)
0 follower

9 more presentations in this session

Transcoronary transfer of Wharton's jelly mesenchymal pluripotent stem cells in patients with chronic ischaemic heart failure shows safety and unprecedented high-grade myocardial uptake

Speaker: Doctor A. Kozynacka (Krakow, PL)

Access
Abstract
0
Thumbnail

Effect of sacubitril-valsartan in reducing physical frailty in patients with advanced heart failure in waiting list for heart transplantation

Speaker: Doctor G. Benincasa (Naples, IT)

Access
Abstract
Slides
0
Thumbnail

Use of sacubitril-valsartan in an extensive long term follow up cohort in real life

Speaker: Doctor A. Garcia Quintana (Las Palmas de Gran Canaria, ES)

Access
Abstract
Slides
0
Thumbnail

Changes in glycated hemoglobin in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

Access
Slides
0
Thumbnail

Valsartan reduces level of soluble ST2 and left ventricle remodeling in patients with dual chamber pacemaker

Speaker: Mrs E. Radzik (Zabrze, PL)

Access
Abstract
0
Thumbnail

Access the full session

Poster Session 1 - Treatment of the chronic heart failure

Speakers: Doctor X. Chen, Doctor A. Kozynacka, Doctor G. Benincasa, Doctor A. Garcia Quintana, Mrs E. Radzik
Access
0
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk